Perspectives on the development of a therapeutic HER-2 cancer vaccine

Vaccine

Volumn 25, Issue SUPPL. 2, 2007, Pages

  Renard, Valéry ^a   Leach, Dana R ^a  

^a Pharmexa AS   (Denmark)

Author keywords

Antibody; Cancer; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ANTIBODY; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; QS 21; TRASTUZUMAB;

ADJUVANT THERAPY; ANTIBODY RESPONSE; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CANCER PATIENT; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; HEALTH PROGRAM; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; MONKEY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CANCER VACCINES; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MICE; MODELS, ANIMAL; RECEPTOR, ERBB-2;

EID: 34748836419     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.05.060     Document Type: Article

References (39)

1. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 4905 (1989) 707-712
2. Liu E., Thor A., He M., Barcos M., Ljung B.M., Benz C., et al. (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 7 (1992) 1027-1034
3. Valabrega G., Montemurro F., and Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol (2007)
4. Demonty G., Bernard-Marty C., Puglisi F., Mancini I., and Piccart M. Progress and new standards of care in the management of HER-2 positive breast cancer. Eur J Cancer 43 3 (2007) 497-509
5. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 11 (2001) 783-792
6. Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23 19 (2005) 4265-4274
7. Disis M.L., Shiota F.M., and Cheever M.A. Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens. Immunology 93 2 (1998) 192-199
8. Disis M.L., Grabstein K.H., Sleath P.R., and Cheever M.A. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 5 6 (1999) 1289-1297
9. Disis M.L., Rinn K., Knutson K.L., Davis D., Caron D., Dela R.C., et al. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood 99 8 (2002) 2845-2850
10. Disis M.L., Gooley T.A., Rinn K., Davis D., Piepkorn M., Cheever M.A., et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20 11 (2002) 2624-2632
11. Disis M.L., Goodell V., Schiffman K., and Knutson K.L. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J Clin Immunol 24 5 (2004) 571-578
12. Disis M.L., Schiffman K., Guthrie K., Salazar L.G., Knutson K.L., Goodell V., et al. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein-based vaccine. J Clin Oncol 22 10 (2004) 1916-1925
13. Salazar L.G., Fikes J., Southwood S., Ishioka G., Knutson K.L., Gooley T.A., et al. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 9 15 (2003) 5559-5565
14. Knutson K.L., Schiffman K., Cheever M.A., and Disis M.L. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 8 5 (2002) 1014-1018
15. McNeel D.G., Knutson K.L., Schiffman K., Davis D.R., Caron D., and Disis M.L. Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant. J Clin Immunol 23 1 (2003) 62-72
16. Peoples G.E., Gurney J.M., Hueman M.T., Woll M.M., Ryan G.B., Storrer C.E., et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 23 30 (2005) 7536-7545
17. Hueman M.T., Dehqanzada Z.A., Novak T.E., Gurney J.M., Woll M.M., Ryan G.B., et al. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. Clin Cancer Res 11 20 (2005) 7470-7479
18. Murray J.L., Gillogly M.E., Przepiorka D., Brewer H., Ibrahim N.K., Booser D.J., et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 8 11 (2002) 3407-3418
19. Zaks T.Z., and Rosenberg S.A. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 58 21 (1998) 4902-4908
20. Daniel D., Chiu C., Giraudo E., Inoue M., Mizzen L.A., Chu N.R., et al. CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res 65 5 (2005) 2018-2025
21. Dudley M.E., Wunderlich J., Nishimura M.I., Yu D., Yang J.C., Topalian S.L., et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 24 4 (2001) 363-373
22. Egilmez N.K., Hess S.D., Chen F.A., Takita H., Conway T.F., and Bankert R.B. Human CD4+ effector T cells mediate indirect interleukin-12- and interferon-gamma-dependent suppression of autologous HLA-negative lung tumor xenografts in severe combined immunodeficient mice. Cancer Res 62 9 (2002) 2611-2617
23. Greenberg P.D., Kern D.E., and Cheever M.A. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med 161 5 (1985) 1122-1134
24. Segal B.M., Glass D.D., and Shevach E.M. Cutting edge: IL-10-producing CD4+ T cells mediate tumor rejection. J Immunol 168 1-4 (2002) [(GENERIC) Ref Type: Generic]
25. Shedlock D.J., and Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300 5617 (2003) 337-339
26. Sun J.C., and Bevan M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300 5617 (2003) 339-342
27. Renard V., Sonderbye L., Ebbehoj K., Rasmussen P.B., Gregorius K., Gottschalk T., et al. HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice. J Immunol 171 3 (2003) 1588-1595
28. Steinaa L., Rasmussen P.B., Rygaard J., Mouritsen S., and Gautam A. Generation of autoreactive CTL by tumour vaccines containing foreign T helper epitopes. Scand J Immunol 65 3 (2007) 240-248
29. Steinaa L., Rasmussen P.B., Wegener A.M., Sonderbye L., Leach D.R., Rygaard J., et al. Linked foreign T-cell help activates self-reactive CTL and inhibits tumor growth. J Immunol 175 1 (2005) 329-334
30. Hertz M., Mahalingam S., Dalum I., Klysner S., Mattes J., Neisig A., et al. Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma. J Immunol 167 7 (2001) 3792-3799
31. Dalum I., Butler D.M., Jensen M.R., Hindersson P., Steinaa L., Waterston A.M., et al. Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol 17 7 (1999) 666-669
32. Panina-Bordignon P., Tan A., Termijtelen A., Demotz S., Corradin G., and Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 19 12 (1989) 2237-2242
33. Muller W.J., Sinn E., Pattengale P.K., Wallace R., and Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54 1 (1988) 105-115
34. Kensil C.R., Patel U., Lennick M., and Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol 146 2 (1991) 431-437
35. Immunopotentiators in modern vaccines. In: Kensil C.R., Schijns V., and O'Hagan D. (Eds). Immunomodulatory adjuvants from Quillaja saponaria (2006), Elsevier, London 109-122
36. Shukla H.S., Hughes L.E., Whitehead R.H., and Newcombe R.G. Long-term follow-up of general immune competence in breast cancer. II. Sequential pre- and post-treatment levels: a 10 year study. Cancer Immunol Immunother 21 1 (1986) 6-11
37. Kensil C.R., Soltysik S., Wheeler D.A., and Wu J.Y. Structure/function studies on QS-21, a unique immunological adjuvant from Quillaja saponaria. Adv Exp Med Biol 404 (1996) 165-172
38. Kirkwood J.M., Ibrahim J.G., Sosman J.A., Sondak V.K., Agarwala S.S., Ernstoff M.S., et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19 9 (2001) 2370-2380
39. Gonzalez G., Crombet T., Catala M., Mirabal V., Hernandez J.C., Gonzalez Y., et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol 9 4 (1998) 431-435